CorMedix: The Undervalued Breakthrough

Core Insights - CorMedix has recently achieved profitability after years of losses, marking a significant turnaround for the company [1] - The company's stock price has increased by 170%, yet it still trades at a modest forward P/E ratio of 8x, indicating potential value [1] Financial Performance - The transition to profitability occurred rapidly, suggesting effective management and operational improvements [1] - The forward P/E ratio of 8x implies that the stock may be undervalued compared to its earnings potential [1]